Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.55 |
| ▸ | CA1 | P00915 | 5/20 | 0.55 |
| ▸ | CA2 | P00918 | 5/20 | 0.55 |
| ▸ | CA7 | P43166 | 5/20 | 0.55 |
| ▸ | CA9 | Q16790 | 5/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.55 |
| ▸ | ESR1 | P03372 | 1/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | GABRA1 | P14867 | 7/20 | 0.49 |
| ▸ | GABRG2 | P18507 | 7/20 | 0.49 |
| ▸ | GABRB3 | P28472 | 7/20 | 0.49 |
| ▸ | GABRA5 | P31644 | 7/20 | 0.49 |
| ▸ | GABRA3 | P34903 | 7/20 | 0.49 |
| ▸ | GABRA2 | P47869 | 7/20 | 0.49 |
| ▸ | GABRA4 | P48169 | 7/20 | 0.49 |
| ▸ | GABRA6 | Q16445 | 7/20 | 0.49 |
| ▸ | GABRP | O00591 | 6/20 | 0.49 |
| ▸ | GABRD | O14764 | 6/20 | 0.49 |
| ▸ | GABRB1 | P18505 | 6/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11633585 | 0.84 | CA12 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL82426 | 0.84 | CYP1A2 (0.55) | CYP1A2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL31172628 | 0.84 | CYP1A2 (0.55) | CYP1A2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL1971939 | 0.82 | MAPK1 (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL10003611 | 0.82 | CYP1A2 (0.53) | CYP1A2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL29637478 | 0.82 | MAPK1 (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL129659 | 0.81 | CYP1A2 (0.51) | CA12CA1CA2CA7CA9 | |
| SCHEMBL435154 | 0.81 | GABRA2 (0.57) | CA12CA1CA2CA7CA9 | |
| SCHEMBL347328 | 0.81 | CYP1A2 (0.51) | CYP1A2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL754777 | 0.81 | CYP1A2 (0.56) | CYP1A2GABRA1GABRG2GABRB3GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108239089-B | Method for synthesizing avibactam sodium | 浙江医药股份有限公司新昌制药厂 | 2020-05-22 | — | — | CN | disclosed |
| EP-3632899-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | RaQualia Pharma Inc. (JP) | 2020-04-08 | — | — | EP | disclosed |
| EP-2427456-B1 | ISOXAZOLE-PYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2020-02-05 | — | — | EP | disclosed |
| EP-2435407-B1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | RAQUALIA PHARMA INC (JP) | 2019-12-25 | — | — | EP | disclosed |
| CN-108239019-A | The synthetic method of one kind (2S, 5S or 5R)-N- tertbutyloxycarbonyls -5- hydroxyls -2-piperidinecarboxylic acid ethyl ester | 浙江医药股份有限公司新昌制药厂 | 2018-07-03 | — | — | CN | disclosed |
| EP-3002278-B1 | GUANIDINE COMPOUND | ASTELLAS PHARMA INC (JP) | 2017-04-19 | — | — | EP | disclosed |
| US-9556160-B2 | Guanidine compound | ASTELLAS PHARMA INC. (JP) | 2017-01-31 | — | — | US | disclosed |
| US-9556160-B2 | Guanidine compound | ASTELLAS PHARMA INC. (JP) | 2017-01-31 | — | — | US | disclosed |
| US-9522140-B2 | Aryl substituted carboxamide derivatives as calcium or sodium channel blockers | RAQUALIA PHARMA INC. (JP) | 2016-12-20 | — | — | US | disclosed |
| EP-2695881-B1 | GUANIDINE COMPOUND | ASTELLAS PHARMA INC (JP) | 2016-04-27 | — | — | EP | disclosed |
| US-20070249659-A1 | melanin concentrating hormone receptor antagonist; preventing or treating vascular system diseases, nervous system disorders, metabolic disorders, urogenital diseases, respiratory diseases disorders; N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-3-fluoro-4-(pyridin-2-ylmethoxy)benzamide | BANYU PHARMACEUTICAL., LTD. (JP) | 2007-10-25 | — | — | US | disclosed |
| EP-1748048-A1 | IMIDAZOPYRIDINE COMPOUND | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-01-31 | — | — | EP | disclosed |
| WO-2007008963-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007008963-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-01-18 | — | — | WO | disclosed |
| US-20070015734-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-01-18 | — | — | US | disclosed |
| US-20070015734-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-01-18 | — | — | US | disclosed |
| US-20070015734-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-01-18 | — | — | US | disclosed |
| EP-1702919-A1 | NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-09-20 | — | — | EP | disclosed |
| US-20060116364-A1 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | EISAI CO., LTD. (JP) | 2006-06-01 | — | — | US | disclosed |
| EP-1577288-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | Eisai Co., Ltd. (JP) | 2005-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249659-A1 | melanin concentrating hormone receptor antagonist; preventing or treating vascular system diseases, nervous system disorders, metabolic disorders, urogenital diseases, respiratory diseases disorders; N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-3-fluoro-4-(pyridin-2-ylmethoxy)benzamide | MC1R, MCHR2, MCHR1 | CA12 4496/4885CA1 4817/4885CA2 2069/4885 |
| US-20070015734-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | MAOB, MAOA, GPR119 | CA12 4786/4885CA1 4792/4885CA2 3649/4885 |
| US-20060116364-A1 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | BRCA1, BCR, RCC1 | CA12 855/4885CA1 442/4885CA2 981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.